Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 528 - 528

Published: April 17, 2025

Ovarian cancer remains one of the most lethal gynecologic malignancies, primarily due to late-stage diagnosis, high recurrence rates, and development chemoresistance. Although targeted therapies have improved patient outcomes, their efficacy is often limited by off-target toxicity acquired drug resistance. Extracellular vesicles (EVs), nanoscale naturally released cells, emerged as promising carriers for precision delivery. This review provides a comprehensive overview recent advances in EV-based therapeutic strategies ovarian cancer, including delivery chemotherapeutic agents, nucleic acid therapeutics, immunomodulatory molecules. We further explore innovative engineering approaches enhance targeting specificity, such surface modification, cell source selection, biomaterial integration, magnetic nanoparticle-assisted Key translational challenges bringing clinical application are also addressed. Collectively, these insights underscore transformative potential platforms advancing personalized treatment cancer.

Language: Английский

Liquid Biopsy Based on EV Biomarkers: A New Frontier for Early Diagnosis and Prognosis Assessment of Cancer at ESMO 2024

Nano TransMed, Journal Year: 2025, Volume and Issue: unknown, P. 100084 - 100084

Published: May 1, 2025

Language: Английский